The Latest Breaking News from AbbVie

Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis.

Here are five “set-and-forget” dividend stocks.

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

While daily stock price moves tend to dominate headlines, shifts in fundamental ranking scores can often tell a deeper story about a company's trajectory. This week, Benzinga's proprietary Growth, Value, Quality and Momentum data revealed major swings among household names, from electric vehicles to pharmaceuticals and financials.

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean…

AbbVie shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

An easy way to avoid the merits in the latest high-stake health care litigation.

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Sector by sector, U.S. dividend stocks have outperformed so far this year, with historically dividend-friendly industries surpassing those with a more growth-oriented focus.